drugset / Trial / NCT03646968
Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
Timeline
- Start
- 2018-08-01
- Primary completion
- 2024-12-31
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Docetaxel | Small molecule | 175 mg/m2 | Intravenous |